PortalPublikationenUltrahypofractionated Low-Dose Total Skin Electron Beam in A...

Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary Syndrome

Standard

Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary Syndrome. / Elsayad, Khaled; Weishaupt, Carsten; Moustakis, Christos; Danzer, Moritz Fabian; Müller, Elisa Christina; Rolf, Daniel; Stranzenbach, Rene; Livingstone, Elisabeth; Booken, Nina; Stadler, Rudolf; Eich, Hans Theodor.

in: INT J RADIAT ONCOL, Jahrgang 117, Nr. 1, 01.09.2023, S. 164-170.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Elsayad, K, Weishaupt, C, Moustakis, C, Danzer, MF, Müller, EC, Rolf, D, Stranzenbach, R, Livingstone, E, Booken, N, Stadler, R & Eich, HT 2023, 'Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary Syndrome', INT J RADIAT ONCOL, Jg. 117, Nr. 1, S. 164-170. https://doi.org/10.1016/j.ijrobp.2023.02.052

APA

Elsayad, K., Weishaupt, C., Moustakis, C., Danzer, M. F., Müller, E. C., Rolf, D., Stranzenbach, R., Livingstone, E., Booken, N., Stadler, R., & Eich, H. T. (2023). Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary Syndrome. INT J RADIAT ONCOL, 117(1), 164-170. https://doi.org/10.1016/j.ijrobp.2023.02.052

Vancouver

Elsayad K, Weishaupt C, Moustakis C, Danzer MF, Müller EC, Rolf D et al. Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary Syndrome. INT J RADIAT ONCOL. 2023 Sep 1;117(1):164-170. https://doi.org/10.1016/j.ijrobp.2023.02.052

Bibtex

@article{8ab03fecade448c0b292724683b22aa9,
title = "Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and S{\'e}zary Syndrome",
abstract = "PURPOSE: The aim of this study was to assess the safety and efficacy of an ultrahypofractionated low-dose total skin electron beam therapy (TSEBT) regimen in patients with advanced mycosis fungoides (MF) or S{\'e}zary syndrome (SS).METHODS AND MATERIALS: In this multicenter observational study from 5 German centers, 18 total patients with MF or SS underwent TSEBT with a total dose of 8 Gy in 2 fractions. The primary endpoint was the overall response rate.RESULTS: Fifteen of 18 patients with stage IIB-IV MF or SS were heavily pretreated with a median of 4 prior systemic therapies. The overall response rate was 88.9% (95% confidence interval [CI], 65.3-98.6), with 3 complete responses (16.9%; 95% CI, 3.6-41.4). At a median follow-up period of 13 months, the median time to next treatment (TTNT) was 12 months (95% CI, 8.2-15.8), and the median progression-free survival was 8 months (95% CI, 2-14). A significant reduction in the modified severity-weighted assessment tool, total Skindex-29 score (Bonferroni-corrected P < .005), and all subdomains (Bonferroni-corrected P < .05) was observed after TSEBT. Half of the irradiated patients (n = 9) developed grade 2 acute and subacute toxicities. One patient had confirmed grade 3 acute toxicity. Chronic grade 1 toxicity has been observed in 33% of patients. Patients with erythroderma/SS or prior radiation therapy appear at higher risk of skin toxicities.CONCLUSIONS: TSEBT with 8 Gy in 2 fractions achieves good disease control and symptom palliation with acceptable toxicity, greater convenience, and fewer hospital visits.",
keywords = "Humans, Sezary Syndrome/radiotherapy, Skin Neoplasms/radiotherapy, Electrons, Mycosis Fungoides/radiotherapy, Skin",
author = "Khaled Elsayad and Carsten Weishaupt and Christos Moustakis and Danzer, {Moritz Fabian} and M{\"u}ller, {Elisa Christina} and Daniel Rolf and Rene Stranzenbach and Elisabeth Livingstone and Nina Booken and Rudolf Stadler and Eich, {Hans Theodor}",
note = "Copyright {\textcopyright} 2023 Elsevier Inc. All rights reserved.",
year = "2023",
month = sep,
day = "1",
doi = "10.1016/j.ijrobp.2023.02.052",
language = "English",
volume = "117",
pages = "164--170",
journal = "INT J RADIAT ONCOL",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary Syndrome

AU - Elsayad, Khaled

AU - Weishaupt, Carsten

AU - Moustakis, Christos

AU - Danzer, Moritz Fabian

AU - Müller, Elisa Christina

AU - Rolf, Daniel

AU - Stranzenbach, Rene

AU - Livingstone, Elisabeth

AU - Booken, Nina

AU - Stadler, Rudolf

AU - Eich, Hans Theodor

N1 - Copyright © 2023 Elsevier Inc. All rights reserved.

PY - 2023/9/1

Y1 - 2023/9/1

N2 - PURPOSE: The aim of this study was to assess the safety and efficacy of an ultrahypofractionated low-dose total skin electron beam therapy (TSEBT) regimen in patients with advanced mycosis fungoides (MF) or Sézary syndrome (SS).METHODS AND MATERIALS: In this multicenter observational study from 5 German centers, 18 total patients with MF or SS underwent TSEBT with a total dose of 8 Gy in 2 fractions. The primary endpoint was the overall response rate.RESULTS: Fifteen of 18 patients with stage IIB-IV MF or SS were heavily pretreated with a median of 4 prior systemic therapies. The overall response rate was 88.9% (95% confidence interval [CI], 65.3-98.6), with 3 complete responses (16.9%; 95% CI, 3.6-41.4). At a median follow-up period of 13 months, the median time to next treatment (TTNT) was 12 months (95% CI, 8.2-15.8), and the median progression-free survival was 8 months (95% CI, 2-14). A significant reduction in the modified severity-weighted assessment tool, total Skindex-29 score (Bonferroni-corrected P < .005), and all subdomains (Bonferroni-corrected P < .05) was observed after TSEBT. Half of the irradiated patients (n = 9) developed grade 2 acute and subacute toxicities. One patient had confirmed grade 3 acute toxicity. Chronic grade 1 toxicity has been observed in 33% of patients. Patients with erythroderma/SS or prior radiation therapy appear at higher risk of skin toxicities.CONCLUSIONS: TSEBT with 8 Gy in 2 fractions achieves good disease control and symptom palliation with acceptable toxicity, greater convenience, and fewer hospital visits.

AB - PURPOSE: The aim of this study was to assess the safety and efficacy of an ultrahypofractionated low-dose total skin electron beam therapy (TSEBT) regimen in patients with advanced mycosis fungoides (MF) or Sézary syndrome (SS).METHODS AND MATERIALS: In this multicenter observational study from 5 German centers, 18 total patients with MF or SS underwent TSEBT with a total dose of 8 Gy in 2 fractions. The primary endpoint was the overall response rate.RESULTS: Fifteen of 18 patients with stage IIB-IV MF or SS were heavily pretreated with a median of 4 prior systemic therapies. The overall response rate was 88.9% (95% confidence interval [CI], 65.3-98.6), with 3 complete responses (16.9%; 95% CI, 3.6-41.4). At a median follow-up period of 13 months, the median time to next treatment (TTNT) was 12 months (95% CI, 8.2-15.8), and the median progression-free survival was 8 months (95% CI, 2-14). A significant reduction in the modified severity-weighted assessment tool, total Skindex-29 score (Bonferroni-corrected P < .005), and all subdomains (Bonferroni-corrected P < .05) was observed after TSEBT. Half of the irradiated patients (n = 9) developed grade 2 acute and subacute toxicities. One patient had confirmed grade 3 acute toxicity. Chronic grade 1 toxicity has been observed in 33% of patients. Patients with erythroderma/SS or prior radiation therapy appear at higher risk of skin toxicities.CONCLUSIONS: TSEBT with 8 Gy in 2 fractions achieves good disease control and symptom palliation with acceptable toxicity, greater convenience, and fewer hospital visits.

KW - Humans

KW - Sezary Syndrome/radiotherapy

KW - Skin Neoplasms/radiotherapy

KW - Electrons

KW - Mycosis Fungoides/radiotherapy

KW - Skin

U2 - 10.1016/j.ijrobp.2023.02.052

DO - 10.1016/j.ijrobp.2023.02.052

M3 - SCORING: Journal article

C2 - 36893819

VL - 117

SP - 164

EP - 170

JO - INT J RADIAT ONCOL

JF - INT J RADIAT ONCOL

SN - 0360-3016

IS - 1

ER -